| Metformin and cancer: licence to heal? | |
| | |
MedLine Citation:
|
PMID: 20557275 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus is associated with increased risk of malignancy (mainly cancer of the pancreas, breast, colon, endometrium and bladder). In addition, there is evidence that antidiabetic medication may itself affect the risk of cancer. Importantly, metformin is nowadays emerging as an agent that has the potential to protect from cancer. Population studies have shown that metformin is associated with a significant reduction of neoplasias in general (and cancer of the breast and prostate, in particular). These observations are supported by in vitro and in vivo evidence that metformin inhibits the growth of cancer cells. The mechanisms underlying this protective potential of metformin are not completely understood. While other mechanisms have also been proposed, the protective action of metformin appears to be exerted by two main pathways. The first involves reduction of endogenous hyperinsulinemia. The second pathway relates to the activation of adenosine monophosphate-activated protein kinase (AMPK), which is recognized to inhibit cellular protein synthesis and growth. Whatever the precise mechanism, any reduction in the risk for cancer may be far-reaching, and this favorable effect adds to the clinical value of metformin as the mainstay of antidiabetic treatment. |
| | |
Authors:
|
Nikolaos Papanas; Efstratios Maltezos; Dimitri P Mikhailidis |
Related Documents
:
|
19372545 - Amp-activated protein kinase promotes human prostate cancer cell growth and survival. 189915 - Effect of prolactin on growth and the estrogen receptor level of human breast cancer ce... 22750895 - Talking with death at a diner: young women's online narratives of cancer. 12200455 - Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of ... 16204695 - Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. 2185865 - Final report of the general clinical results of the british institute of radiology frac... |
Publication Detail:
|
Type: Editorial |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 19 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-15 Completed Date: 2010-10-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 913-7 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cell Line, Tumor Diabetes Mellitus, Type 2 / complications, drug therapy Female Humans Hyperinsulinism / metabolism, prevention & control Hypoglycemic Agents / therapeutic use Metformin / therapeutic use* Mice Mice, Transgenic Neoplasms / drug therapy, prevention & control* Protein Kinases / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 657-24-9/Metformin; EC 2.7.-/Protein Kinases; EC 2.7.1.-/AMP-activated protein kinase kinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ambient noise levels and infant hearing screening programs in developing countries: An observational...
Next Document: Novel dual Src/Abl inhibitors for hematologic and solid malignancies.